Aurobindo Pharma (BOM:524804) Other Current Liabilities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524804 Aurobindo Pharma Ltd BOM:524804
88 GF Score
Price ₹1,625.00
GF Value ₹1,395.23
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Aurobindo Pharma Other Current Liabilities?

Aurobindo Pharma BOM:524804 -1.99% 88 Other Current Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:524804 with a GF Score™ of 88/100 and a GF Value™ of ₹1,395.23 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Aurobindo Pharma's other current liabilities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Aurobindo Pharma's quarterly other current liabilities increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹41,305 Mil) but then declined from Mar. 2026 (₹41,305 Mil) to Jun. 2026 (₹0 Mil).

Aurobindo Pharma's annual other current liabilities increased from Mar. 2024 (₹23,514 Mil) to Mar. 2025 (₹32,182 Mil) and increased from Mar. 2025 (₹32,182 Mil) to Mar. 2026 (₹41,305 Mil).

Aurobindo Pharma Other Current Liabilities Related Terms

Aurobindo Pharma Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Aurobindo Pharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurobindo Pharma Other Current Liabilities Chart

Aurobindo Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20,578.70 23,926.00 23,514.40 32,181.50 41,305.10

Aurobindo Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 38,317.60 0.00 41,305.10 0.00
BOM:524804
88GF Score
Aurobindo Pharma Ltd BOM:524804
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurobindo Pharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹0 Mil mean?
Aurobindo Pharma (BOM:524804) has a Other Current Liabilities of ₹0 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aurobindo Pharma.
Is Aurobindo Pharma's Other Current Liabilities too high?
Aurobindo Pharma's current Other Current Liabilities is ₹0 Mil. Overall, Aurobindo Pharma has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurobindo Pharma's Other Current Liabilities compare to ZTS?
Aurobindo Pharma's Other Current Liabilities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aurobindo Pharma. Aurobindo Pharma's current Other Current Liabilities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurobindo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Aurobindo Pharma (BOM:524804) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,395.23, compared to a current price of ₹1,625.00 — trading 16.5% above its estimated fair value. The current Other Current Liabilities is ₹0 Mil. Aurobindo Pharma's overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Aurobindo Pharma (BOM:524804), the current Other Current Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?

Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued. The current stock price of ₹1,625.00 is trading 16.5% above its estimated GF Value™ of ₹1,395.23. GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524804:

  • Other Current Liabilities: ₹0 Mil
  • GF Value™: ₹1,395.23 vs. price of ₹1,625.00 (16.5% above fair value)
  • GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurobindo Pharma Business Description

Other Exchanges AUROPHARMA:India
Address Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
88GF Score

Get the complete analysis for BOM:524804

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,625.00
Price
₹1,395.23
GF Value